Milica Medved to Male
This is a "connection" page, showing publications Milica Medved has written about Male.
Connection Strength
0.234
-
High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magn Reson Med. 2021 09; 86(3):1505-1513.
Score: 0.041
-
High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol. 2014 Jul; 203(1):85-90.
Score: 0.026
-
MR imaging of the prostate and adjacent anatomic structures before, during, and after ejaculation: qualitative and quantitative evaluation. Radiology. 2014 May; 271(2):452-60.
Score: 0.025
-
Directional and inter-acquisition variability in diffusion-weighted imaging and editing for restricted diffusion. Magn Reson Med. 2022 11; 88(5):2298-2310.
Score: 0.011
-
Physically implausible signals as a quantitative quality assessment metric in prostate diffusion-weighted MR imaging. Abdom Radiol (NY). 2022 07; 47(7):2500-2508.
Score: 0.011
-
Development of a standardized MRI protocol for pancreas assessment in humans. PLoS One. 2021; 16(8):e0256029.
Score: 0.010
-
Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data. Phys Med Biol. 2021 01 22; 66(2):025002.
Score: 0.010
-
T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
Score: 0.010
-
A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Phys Med Biol. 2019 08 07; 64(15):155012.
Score: 0.009
-
Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
Score: 0.009
-
Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
Score: 0.008
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
Score: 0.007
-
Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score. AJR Am J Roentgenol. 2016 Sep; 207(3):592-8.
Score: 0.007
-
Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
Score: 0.007
-
Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging. 2015 Oct; 40(7):2523-8.
Score: 0.007
-
Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
Score: 0.006
-
Hybrid multidimensional T(2) and diffusion-weighted MRI for prostate cancer detection. J Magn Reson Imaging. 2014 Apr; 39(4):781-8.
Score: 0.006
-
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
Score: 0.004
-
Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR images. Magn Reson Med. 2009 Feb; 61(2):291-8.
Score: 0.004
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.004
-
Multi-slice DCE-MRI data using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors. MAGMA. 2006 Feb; 19(1):15-21.
Score: 0.004
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
Score: 0.003
-
New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med. 2004 Mar; 51(3):487-94.
Score: 0.003